Patents by Inventor Tae-Gon Baik

Tae-Gon Baik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190008785
    Abstract: The present invention relates to a pharmaceutical composition comprising dutasteride and propylene glycol monolaurate, which improves the stability of dutasteride, which is a poorly soluble drug as a 5-alpha reductase inhibitor, and a process for its preparation. More particularly, the present invention also relates to a capsule formulation which is smaller in size than a commercial dutasteride capsule formulation (AVODARTĀ®), but has the equivalent dissolution rate by preparing a pharmaceutical composition comprising propylene glycol monolaurate and dutasteride, which can improve the stability of the dutasteride. A dutasteride formulation having enhanced patient's compliance and improved stability and a method for producing the same are provided.
    Type: Application
    Filed: December 29, 2016
    Publication date: January 10, 2019
    Inventors: Tae Gon Baik, Seyeon Kim, Kyeongjin Ahn, Ju-Hee Kim, Young-Joon Park
  • Patent number: 9815840
    Abstract: The present invention relates to a pyrrolopyridazine derivative represented by Formula 1 of the detailed description, or a pharmaceutically acceptable salt thereof. The compound according to the present invention and a pharmaceutically acceptable salt thereof can inhibit the activity of protein kinase(s), and thus are useful for preventing or treating diseases related thereto.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: November 14, 2017
    Assignee: The Asan Foundation
    Inventors: Tae Gon Baik, Won-Hyuk Jung, Seung In Kim, Seung Chan Kim, Sook Kyung Park, Su Yeon Jung, Seung Hee Ji, So Young Ki, Min Cheol Kim, Eun Young Lee, Eun Mi Hong
  • Publication number: 20160207931
    Abstract: The present invention relates to a pyrrolopyridazine derivative represented by Formula 1 of the detailed description, or a pharmaceutically acceptable salt thereof. The compound according to the present invention and a pharmaceutically acceptable salt thereof can inhibit the activity of protein kinase(s), and thus are useful for preventing or treating diseases related thereto.
    Type: Application
    Filed: August 29, 2014
    Publication date: July 21, 2016
    Applicant: CJ Healthcare Corporation
    Inventors: Tae Gon BAIK, Won-Hyuk JUNG, Seung In KIM, Seung Chan KIM, Sook Kyung PARK, Su Yeon JUNG, Seung Hee JI, So Young KI, Min Cheol KIM, Eun Young LEE, Eun Mi HONG
  • Patent number: 8710038
    Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention.
    Type: Grant
    Filed: September 15, 2005
    Date of Patent: April 29, 2014
    Assignee: Exelixis, Inc.
    Inventors: Tae-Gon Baik, Chris A. Buhr, Sunghoon Ma, John M. Nuss, Zerom Tesfai, Longcheng Wang, Bryan K. S. Yeung
  • Patent number: 8247408
    Abstract: The invention is directed to Compounds of Formula I and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
    Type: Grant
    Filed: October 9, 2006
    Date of Patent: August 21, 2012
    Assignee: Exelixis, Inc.
    Inventors: Tae-Gon Baik, Chris A. Buhr, Katherine Lara, Sunghoon Ma, Longcheng Wang, Bryan K. S. Yeung
  • Patent number: 8101622
    Abstract: The invention is directed to Compounds of Formula I: optionally as a single stereoisomer or mixture of stereoisomers thereof, and additionally optionally as a pharmaceutically acceptable salt thereof; as well as methods of making and using the compounds.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: January 24, 2012
    Assignee: Exelixis, Inc.
    Inventors: Tae-Gon Baik, Sunghoon Ma, Chris A. Buhr, John M. Nuss
  • Patent number: 8044062
    Abstract: The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
    Type: Grant
    Filed: October 9, 2006
    Date of Patent: October 25, 2011
    Assignee: Exelixis, Inc.
    Inventors: Tae-Gon Baik, Chris A. Buhr, Katherine Lara, Sunghoon Ma, Morrison Mac, John M. Nuss, Longcheng Wang, Yong Wang, Bryan K. S. Yeung
  • Publication number: 20110237608
    Abstract: The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
    Type: Application
    Filed: June 2, 2011
    Publication date: September 29, 2011
    Applicant: Exelixis, Inc.
    Inventors: Tae-Gon Baik, Chris A. Buhr, Katherine Lara, Sunghoon Ma, Morrison Mac, John M. Nuss, Longcheng Wang, Yong Wang, Bryan K.S. Yeung
  • Patent number: 8012956
    Abstract: A compound according to Formula I or II: wherein R1, R1b, R2, L1, and L2 and L2b are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: September 6, 2011
    Assignee: Exelixis, Inc.
    Inventors: Kenneth D. Rice, Naing Aay, Neel Kumar Anand, Arlyn Arcalas, Tae-Gon Baik, Charles M. Blazey, Owen Joseph Bowles, Chris A. Buhr, Joerg Bussenius, Simona Costanzo, Jeffrey Kimo Curtis, Steven Charles Defina, Larisa Dubenko, Abigail R. Kennedy, Angie Inyoung Kim, Katherine Lara, Sunghoon Ma, Jean-Claire Limun Manalo, Csaba J. Peto, Tsze H. Tsang, Longcheng Wang
  • Patent number: 7704995
    Abstract: This invention relates to compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and to pharmaceutical compositions containing such compounds. Even more specifically, the invention relates to compounds that inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Methods of therapeutically or prophylactically using the compounds and compositions to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer, as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amounts of such compounds.
    Type: Grant
    Filed: May 2, 2003
    Date of Patent: April 27, 2010
    Assignee: Exelixis, Inc.
    Inventors: Chris A. Buhr, Tae-Gon Baik, Sunghoon Ma, Zerom Tesfai, Longcheng Wang, Erick Wang Co, Sergey Epshteyn, Abigail R Kennedy, Baili Chen, Larisa Dubenko, Neel Kumar Anand, Tsze H. Tsang, John M. Nuss, Csaba J Peto, Kenneth D. Rice, Mohamed Abdulkader Ibrahim, Kevin Luke Schnepp, Xian Shi, James William Leahy, Jeff Chen, Lisa Esther Dalrymple, Timothy Patrick Forsyth, Tai Phat Huynh, Grace Mann, Larry Wayne Mann, Craig Stacy Takeuchi, Peter Lamb, David J. Matthews, Nicole Miller
  • Publication number: 20100087456
    Abstract: The invention is directed to Compounds of Formula I: optionally as a single stereoisomer or mixture of stereoisomers thereof, and additionally optionally as a pharmaceutically acceptable salt thereof; as well as methods of making and using the compounds.
    Type: Application
    Filed: September 29, 2009
    Publication date: April 8, 2010
    Applicant: Exelixis, Inc.
    Inventors: Tae-Gon Baik, Sunghoon Ma, Chris A. Buhr, John M. Nuss
  • Publication number: 20090270430
    Abstract: The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
    Type: Application
    Filed: October 9, 2006
    Publication date: October 29, 2009
    Applicant: Exelixix, Inc.
    Inventors: Tae-Gon Baik, Chris A. Buhr, Katherine Lara, Sunghoon Ma, Morrison Mac, John M. Nuss, Longcheng Wang, Yong Wang, Bryan K.S. Yeung
  • Publication number: 20090203577
    Abstract: The present invention relates to compounds of formula I, which exhibit affinity for the farnesoid X receptor.
    Type: Application
    Filed: December 12, 2006
    Publication date: August 13, 2009
    Applicant: EXELIXIS, INC.
    Inventors: Tae-Gon Baik, Chris A. Buhr, Brett B. Busch, Diva Sze-Ming Chan, Brenton T. Flatt, Xiao-Hui Gu, Vasu Jammalamadaka, Richard George Khoury, Katherine Lara, Sunghoon Ma, Richard Martin, Raju Mohan, John M. Nuss, Jason Jevious Parks, Jason H. Wu, Bryan K. S. Yeung, Wei Xu, Tie-Lin Wang, Longcheng Wang
  • Publication number: 20090163471
    Abstract: A compound according to Formula I or II: wherein R1, R1b, R2, L1, and L2 and L2b are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: October 27, 2008
    Publication date: June 25, 2009
    Inventors: Kenneth D. Rice, Naing Aay, Neel Kumar Anand, Arlyn Arcalas, Tae-Gon Baik, Charles M. Blazey, Owen Joseph Bowles, Chris A. Buhr, Joerg Bussenius, Simona Costanzo, Jeffrey Kimo Curtis, Steven Charles Defina, Larisa Dubenko, Abigail R. Kennedy, Angie Inyoung Kim, Katherine Lara, Sunghoon Ma, Jean-Claire Limun Manalo, Csaba J. Peto, Tsze H. Tsang, Longcheng Wang
  • Publication number: 20090062274
    Abstract: The invention is directed to Compounds of Formula I and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
    Type: Application
    Filed: October 9, 2006
    Publication date: March 5, 2009
    Applicant: Exelixis, Inc
    Inventors: Tae-Gon Baik, Chris A. Buhr, Katherine Lara, Sunghoon Ma, Longcheng Wang, Bryan K.S. Yeung
  • Publication number: 20070293507
    Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention.
    Type: Application
    Filed: September 15, 2005
    Publication date: December 20, 2007
    Applicant: EXELIXIS, INC.
    Inventors: Tae-Gon Baik, Chris Buhr, Sunghoon Ma, John Nuss, Zerom Tesfai, Longcheng Wang, Bryan Yeung
  • Publication number: 20060211709
    Abstract: Substituted aryl 1,4-pyrazine derivatives and their use in treating anxiety disorders, depression and stress related disorders are disclosed.
    Type: Application
    Filed: May 2, 2003
    Publication date: September 21, 2006
    Inventors: Chris Buhr, Tae-Gon Baik, Sunghoon Ma, Zerom Tesfai, Longcheng Wang, Erick Co, Sergey Epshteyn, Abigail Kennedy, Baili Chen, Larisa Dubenko, Neel Anand, Tsze Tsang, John Nuss, Csabaj Peto, Kenneth Rice, Mohamed Ibrahim, Xian Shi, James Leahy, Jeff Chen, Lisa Dalrymple, Timothy Forsyth, Tai Huynh, Grace Mann, Larry Mann, Craig Takeuchi